Genece Health Announces New Performance Data to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024
DEL MAR, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Genece Health, a molecular testing company focused on improving cancer screening for lung, breast, ovarian and other cancers, today announced that four abstracts demonstrating their deep-learning AI and liquid biopsy technology’s performance were selected for presentation at the upcoming 2024 American Association for Cancer Research (AACR), taking place April 5-10, 2024, in San Diego, CA. This will be the first time performance data from the company will be shared publicly.The abstracts will be available on the AACR website and poster presentation details can be found below.
*Subject: Lung cancer test results show high sensitivity and specificity*
* Title:* A Novel Liquid Biopsy Lung Cancer Detection Method Using a Coverage and Fragment End Motif Machine Learning Analysis
* Session Title: Risk Prediction Modeling, Screening, Early Detection, and Preneoplastic and Tumor Markers*
* Location*: Poster Section 33 Board 3
* Abstract* *Number*: 3448
* Date/Time:* Monday April 8, 1:30PM to 5:00PM
* Presenting Author: Bryan Leatham*
*Subject: A powerful new Machine Learning approach to increase sensitivity *
* Title*: REFINE Method: Novel Strategy for Signal Enhancement
* Session Title: Artificial Intelligence and Machine/Deep Learning 3*
* Location*: Poster Section 36 Board 24
* Abstract* *Number*: 4928
* Date/Time:* Tuesday April 9, 9:00AM to 12:30PM
* Presenting Author: Michael Wang, PhD*
*Subject: Promising initial results in breast cancer for screening patients with dense breast tissue*
* Title: *Improving Cancer Screening Performance for Women with Dense Breast Tissue
* Session Title: Population-Based Screening*
* Location*: Poster Section 32 Board 13
* Abstract* *Number*: 4796
* Date/Time:* Tuesday April 9, 9:00AM to 12:30PM
* Presenting Author: Molly Smith*
*Subject: Robust performance even when cfDNA inputs decrease*
* Title: *Optimization of a Liquid Biopsy Assay to Accommodate Low cfDNA Samples and Increase Throughput
* Session Title: Advances in Genomic Sequencing Platforms, Methodologies, and Interpretation 1 *
* Location*: Poster Section 14 Board 11
* Abstract* *Number*: 323
* Date/Time:* Sunday April 7, 1:30PM to 5:00PM
* Presenting Author: Michael Salmans, PhD*
More information can be found on the AACR meeting *website*.
*About Genece Health*
Genece leverages a proprietary liquid biopsy and deep-learning AI technology for early cancer detection. The Company was founded in 2022 through a strategic partnership with GC Genome, the genomics arm of GC Corporation, a leading life sciences company in South Korea. Genece focuses on the acute need for targeted screening tools to support decision-making when a mass or lump is detected through imaging, empowering physicians to make informed decisions and improve care. The Company’s initial applications include high-mortality and women’s health cancers. For more information, visit genecehealth.com or follow Genece on Linkedin.
*Investor Contact:*
investors@genecehealth.com